40 Hz auditory stimulation may help clear Alzheimer's brain plaques
40 Hz auditory stimulation increases amyloid clearance markers in the brains of aged primates and produces lasting effects, supporting its potential as a non-invasive Alzheimer's disease therapy.
Scientists at the Kunming Institute of Zoology, Chinese Academy of Sciences have demonstrated for the first time in non-human primates that 40 Hz sound stimulation can significantly increase beta-amyloid levels in the cerebrospinal fluid of aged rhesus monkeys. Notably, this effect persisted for more than five weeks after treatment ended.
Published in the Proceedings of the National Academy of Sciences (PNAS), this study provides the first experimental evidence in non-human primates that 40 Hz stimulation could serve as a non-invasive physical therapy for Alzheimer's disease (AD).
Auditory stimulation drives amyloid clearance
In a randomized controlled trial, the experimental group received one hour of 40 Hz auditory stimulation daily for seven consecutive days. After treatment, the concentrations of Aβ42 and Aβ40 in the monkeys' cerebrospinal fluid increased by 205.61% and 201.00%, respectively, compared to baseline, with statistically significant differences. These changes are consistent with previous findings in mice and support the hypothesis that 40 Hz stimulation may promote the transfer of beta-amyloid from brain tissue to cerebrospinal fluid, a process believed to reflect enhanced clearance.
Importantly, when the researchers measured CSF Aβ levels again 35 days after stimulation ended, the concentrations remained elevated and did not significantly decrease from the immediate post-treatment values. This lasting effect has not been reported in mouse studies. Such a prolonged response further supports the feasibility of 40 Hz stimulation as a potential non-invasive Alzheimer's therapy and highlights the importance of aged rhesus monkeys in translational Alzheimer's research.
A non-invasive alternative to antibody therapy
Currently approved anti-Aβ monoclonal antibody therapies can slow the progression of early AD but carry risks such as brain edema and hemorrhage.
In contrast, 40 Hz auditory stimulation is a low-cost, non-invasive intervention that may offer therapeutic benefits with a higher safety profile. These results suggest that it could be explored as an adjunct or alternative strategy for Alzheimer's treatment.
"Long-term effects of 40 Hz auditory stimulation for Alzheimer's disease: insights from an aged monkey model study," January 5, 2026, Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2529565123
MIT's research on 40 Hz and Alzheimer's
Entrainment is the phenomenon where two or more oscillators synchronize to a common rhythm, occurring in both physical and biological systems. For example, two pendulums swinging in sync, brain waves synchronizing with flashing lights, and individuals in a group unconsciously adjusting their breathing or gestures. It is the process by which one system's rhythm becomes locked to another's, influencing behavior, physiological processes, and even chemical and hormonal systems.
The brain's electrical rhythms can synchronize with external stimuli such as flickering lights, music, or speech.
Soft flickering lights and a steady hum may help slow the progression of Alzheimer's disease. This is the idea behind a new therapy developed by researchers at the Massachusetts Institute of Technology and Massachusetts General Hospital, who reported a small but landmark study with encouraging results over two years.
The therapy, called Gamma Entrainment Using Sensory Stimulation (GENUS), uses synchronized light and sound pulses at 40 Hz, a frequency that appears to restore brain rhythms disrupted by Alzheimer's. For more than two years, five patients with mild Alzheimer's used the device at home for one hour each day.
Healthy brains naturally produce gamma waves (30–100 Hz, the highest-frequency brain waves), which support memory, attention, and sensory processing. In Alzheimer's patients, gamma waves become weaker and more irregular, disrupting communication between brain cells. Early animal studies at MIT showed that restoring these rhythms with flickering lights and sound could reduce accumulations of amyloid and tau proteins, key drivers of Alzheimer's progression.
Each participant used a home device consisting of an LED light panel, a speaker, and a tablet that displayed entertainment content while providing rhythmic stimulation.
The GENUS device emits synchronized light and sound at 40 Hz. This pattern "entrains" the brain to follow the same rhythm. The latest open-label extension study followed five participants for approximately 30 months: three women with late-onset Alzheimer's and two men with early-onset Alzheimer's. This is the longest human test of the method to date.
Results showed that cognitive decline slowed or stopped in patients with late-onset Alzheimer's. MRI scans indicated that while brain volume loss continued over two years, patients with late-onset disease experienced less tissue loss than typically expected.
In two late-onset subjects who provided blood samples, levels of phosphorylated tau 217 dropped sharply—by 47% and 19%, respectively. This protein is closely linked to the formation of tangles, a hallmark of Alzheimer's. Previously, no non-invasive therapy had shown such a significant reduction in human patients.
If future trials confirm these early results, GENUS could redefine Alzheimer's treatment. The idea that light and sound alone could slow brain degeneration offers hope to millions of families seeking non-pharmaceutical therapies.
Source: https://www.yahoo.com/news/articles/study-finds-40hz-sensory-stimulation-115100146.html
